CN119110807A - 抗cd40抗体及其用途 - Google Patents
抗cd40抗体及其用途 Download PDFInfo
- Publication number
- CN119110807A CN119110807A CN202380034047.7A CN202380034047A CN119110807A CN 119110807 A CN119110807 A CN 119110807A CN 202380034047 A CN202380034047 A CN 202380034047A CN 119110807 A CN119110807 A CN 119110807A
- Authority
- CN
- China
- Prior art keywords
- antibody
- seq
- antigen
- amino acid
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2022/087003 | 2022-04-15 | ||
| CN2022087003 | 2022-04-15 | ||
| PCT/CN2023/088417 WO2023198194A1 (en) | 2022-04-15 | 2023-04-14 | Anti-cd40 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119110807A true CN119110807A (zh) | 2024-12-10 |
Family
ID=88329041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380034047.7A Pending CN119110807A (zh) | 2022-04-15 | 2023-04-14 | 抗cd40抗体及其用途 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4508088A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025512025A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250005109A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119110807A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023254322A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3256072A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023198194A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007053661A2 (en) * | 2005-11-01 | 2007-05-10 | Novartis Ag | Uses of anti-cd40 antibodies |
| JO3096B1 (ar) * | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
| AU2016201742B2 (en) * | 2010-11-15 | 2017-11-02 | Novartis Ag | Silent Fc variants of anti-CD40 antibodies |
| HUE065915T2 (hu) * | 2011-03-11 | 2024-06-28 | Beth Israel Deaconess Medical Ct Inc | Anti-CD40 antitestek és alkalmazásaik |
| NO2699601T3 (cg-RX-API-DMAC7.html) * | 2011-04-21 | 2018-06-16 | ||
| WO2020006347A1 (en) * | 2018-06-29 | 2020-01-02 | Boehringer Ingelheim International Gmbh | Anti-cd40 antibodies for use in treating autoimmune disease |
| WO2020014974A1 (en) * | 2018-07-20 | 2020-01-23 | Eucure (Beijing) Biopharma Co., Ltd | Anti-cd40 antibodies and uses thereof |
-
2023
- 2023-04-14 JP JP2024560259A patent/JP2025512025A/ja active Pending
- 2023-04-14 AU AU2023254322A patent/AU2023254322A1/en active Pending
- 2023-04-14 WO PCT/CN2023/088417 patent/WO2023198194A1/en not_active Ceased
- 2023-04-14 CN CN202380034047.7A patent/CN119110807A/zh active Pending
- 2023-04-14 KR KR1020247033695A patent/KR20250005109A/ko active Pending
- 2023-04-14 EP EP23787836.8A patent/EP4508088A4/en active Pending
- 2023-04-14 CA CA3256072A patent/CA3256072A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023198194A1 (en) | 2023-10-19 |
| EP4508088A4 (en) | 2026-04-01 |
| JP2025512025A (ja) | 2025-04-16 |
| KR20250005109A (ko) | 2025-01-09 |
| CA3256072A1 (en) | 2023-10-19 |
| AU2023254322A1 (en) | 2024-10-24 |
| EP4508088A1 (en) | 2025-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240352141A1 (en) | Anti-ox40 antibodies and uses thereof | |
| KR102608723B1 (ko) | 항―pd-1 항체 및 그의 용도 | |
| CN112533950A (zh) | 抗CD3e抗体及其用途 | |
| KR20210062026A (ko) | 항-tnfrsf9 항체 및 그의 용도 | |
| CN112566933B (zh) | 抗cd40抗体及其用途 | |
| CN120152988A (zh) | 抗ccr8抗体及其用途 | |
| CN116848247B (zh) | 抗tnfr2抗体及其用途 | |
| CN119403838A (zh) | 抗siglec15抗体及其用途 | |
| WO2023198194A1 (en) | Anti-cd40 antibodies and uses thereof | |
| HK40117288A (en) | Anti-cd40 antibodies and uses thereof | |
| WO2024175020A1 (en) | Anti-il2ra antibodies and uses thereof | |
| WO2024131716A1 (en) | Anti-pdl1 antibodies and uses thereof | |
| RU2783314C2 (ru) | Антитела против ox40 и их применения | |
| RU2796413C2 (ru) | Антитела против cd40 и их применения | |
| HK40116270A (en) | Anti-siglec15 antibodies and uses thereof | |
| HK40047604A (en) | Anti-cd40 antibodies and uses thereof | |
| HK40047604B (zh) | 抗cd40抗体及其用途 | |
| HK40039579A (en) | Anti-ox40 antibodies and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40117288 Country of ref document: HK |